{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T05:26:41Z","timestamp":1769232401597,"version":"3.49.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.clindermatol.2017.08.007","type":"journal-article","created":{"date-parts":[[2017,8,4]],"date-time":"2017-08-04T23:48:15Z","timestamp":1501890495000},"page":"566-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cutaneous adverse drug reactions: Kids are not just little people"],"prefix":"10.1016","volume":"35","author":[{"given":"Reid","family":"Waldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Whitaker-Worth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane M.","family":"Grant-Kels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2017.08.007_bb0005","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMcp1104080","article-title":"Exanthematous drug eruptions","volume":"366","author":"Stern","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0010","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5114\/pdia.2014.43881","article-title":"Cutaneous drug reactions in children: A multicentric study","volume":"31","author":"Dilek","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0015","first-page":"765","article-title":"Rates of cutaneous reactions to drugs","volume":"137","author":"Bigby","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0020","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1001\/jama.1997.03550220101014","article-title":"Allergic reactions to drugs and biologic agents","volume":"278","author":"DeShazo","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archderm.1997.03890400081011","article-title":"Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes","volume":"133","author":"Barbaud","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0030","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00128071-200304060-00005","article-title":"Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: Implications for management","volume":"4","author":"Crowson","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0091-6749(94)90202-X","article-title":"Sulfonamide-reactive lymphocytes detected at very low frequency in the peripheral blood of patients with drug-induced eruptions","volume":"94","author":"Kalish","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2310\/6620.2011.10063","article-title":"The potential utility of patch testing in identifying the causative agent of morbilliform drug eruptions","volume":"22","author":"Endo","year":"2011","journal-title":"Dermatitis"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cger.2013.01.008","article-title":"A review of cutaneous drug eruptions","volume":"29","author":"Ahmed","year":"2013","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0050","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archderm.1991.01680040122017","article-title":"Cutaneous drug reactions in human immunodeficiency virus infection","volume":"127","author":"Coopman","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0055","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.clindermatol.2014.02.005","article-title":"An update on pediatric cutaneous drug eruptions","volume":"32","author":"Song","year":"2014","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0060","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/000992289803701002","article-title":"Study of skin rashes after antibiotic use in young children","volume":"37","author":"Huang","year":"1998","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0070","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0025-7125(05)70420-X","article-title":"Pediatric dermatology","volume":"82","author":"Hanson","year":"1998","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0080","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1525-1470.2009.00870.x","article-title":"Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS)","volume":"26","author":"Newell","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0085","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0090","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1365-2133.2003.05584.x","article-title":"A 6-month prospective survey of cutaneous drug reactions in a hospital setting","volume":"149","author":"Fiszenson-Abala","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0095","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong","volume":"167","author":"Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1399-3038.2012.01268.x","article-title":"The association between DRESS and the diminished numbers of peripheral B lymphocytes and natural killer cells: Peripheral B lymphocytes and NK cells in DRESS","volume":"23","author":"Yazicioglu","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0105","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.13592","article-title":"Human herpesvirus 6 involvement in paediatric drug hypersensitivity syndrome","volume":"172","author":"Descamps","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/archderm.140.2.183","article-title":"Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia","volume":"140","author":"Kano","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bjp.0704074","article-title":"Antigenicity and immunogenicity of sulphamethoxazole: Demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo","volume":"133","author":"Naisbitt","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0120","first-page":"357","article-title":"The drug hypersensitivity syndrome: What is the pathogenesis?","volume":"137","author":"Sullivan","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0125","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-4632.2012.05547.x","article-title":"Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome and hepatitis induced by phenytoin: DRESS syndrome and hepatitis induced by phenytoin","volume":"53","author":"Velasco","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1345\/aph.10284","article-title":"Antiepileptic hypersensitivity syndrome in children","volume":"35","author":"Bessmertny","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0135","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1172\/JCI113798","article-title":"Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk","volume":"82","author":"Shear","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0140","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1542\/peds.108.2.485","article-title":"Drug-induced hypersensitivity syndrome in pediatric patients","volume":"108","author":"Carroll","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0145","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0150","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","article-title":"The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations","volume":"156","author":"Shio Shiohara","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0155","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: Part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0160","first-page":"433","article-title":"Use of the lymphocyte transformation test in the diagnosis of DRESS syndrome induced by ceftriaxone and piperacillin-tazobactam: Two case reports","volume":"20","author":"Jurado-Palomo","year":"2010","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0165","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0536.2009.01659.x","article-title":"Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS)","volume":"62","author":"Santiago","year":"2010","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0170","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: Part II. Management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11940-007-0010-9","article-title":"Anticonvulsant hypersensitivity syndrome: Identification and management","volume":"9","author":"Ting","year":"2007","journal-title":"Curr Treatment Opt Neurol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0180","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaad.2014.10.032","article-title":"Therapeutic management of DRESS: A retrospective study of 38 cases","volume":"72","author":"Funck-Brentano","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0185","first-page":"1","article-title":"Successful treatment of antiepileptic drug-induced DRESS syndrome with pulse methylprednisolone","volume":"2013","author":"Kocaoglu","year":"2013","journal-title":"Case Rep Pediatr"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1684\/ejd.2011.1300","article-title":"Ten cases of drug reaction with eosinophilia and systemic symptoms (DRESS) treated with pulsed intravenous methylprednisolone","volume":"21","author":"Natkunarajah","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0195","first-page":"494","article-title":"A case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins","volume":"149","author":"Singer","year":"2013","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0200","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1542\/peds.2012-2117","article-title":"Severe DRESS syndrome managed with therapeutic plasma exchange","volume":"131","author":"Alexander","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0205","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2009.05.046","article-title":"Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis","volume":"62","author":"Shaughnessy","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5414\/CNP64155","article-title":"Vancomycin-induced hypersensitivity reaction with acute renal failure: Resolution following cyclosporine treatment","volume":"64","author":"Zuliani","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0215","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0220","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jaad.2005.09.021","article-title":"Toxic epidermal necrolysis in a mother and fetus","volume":"55","author":"Rodriguez","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0225","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: A pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0235","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0240","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1542\/peds.2010-3322","article-title":"Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children","volume":"128","author":"Finkelstein","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0245","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/clpt.2012.189","article-title":"HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A systematic review","volume":"92","author":"Yip","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0250","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaad.2013.05.003","article-title":"Toxic epidermal necrolysis","volume":"69","author":"Schwartz","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0255","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0260","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0265","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0270","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2125.2010.03764.x","article-title":"Delayed drug hypersensitivity: Models of T-cell stimulation","volume":"71","author":"Adam","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0275","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2012.09.014","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients","volume":"131","author":"Saito","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0280","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jtos.2016.02.001","article-title":"Acute and chronic ophthalmic involvement in Stevens-Johnson syndrome\/toxic epidermal necrolysis\u2014a comprehensive review and guide to therapy. II. Ophthalmic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocular Surface"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00004630-199605000-00009","article-title":"Acute and chronic respiratory complications of toxic epidermal necrolysis","volume":"17","author":"McIvor","year":"1996","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0290","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1346-8138.1998.tb02450.x","article-title":"Toxic epidermal necrolysis with severe gastrointestinal mucosal cell death: A patient who excreted long tubes of dead intestinal epithelium","volume":"25","author":"Sugimoto","year":"1998","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0295","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(96)90297-2","article-title":"Renal involvement in toxic epidermal necrolysis","volume":"34","author":"Blum","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0300","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients\u2014treatment and outcome","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0305","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2230.2010.03826.x","article-title":"Toxic epidermal necrolysis: Retrospective analysis of 21 consecutive cases managed at a tertiary centre","volume":"35","author":"Rajaratnam","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0310","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: A severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0315","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2133.1996.tb03598.x","article-title":"Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"135","author":"Rzany","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0320","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jaad.2011.10.007","article-title":"Prognostic value of histologic features of toxic epidermal necrolysis","volume":"68","author":"Valeyrie-Allanore","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0325","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis: Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0330","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0335","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0340","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1542\/peds.112.6.1430","article-title":"Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: Seven cases and review of the literature","volume":"112","author":"Metry","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0345","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0350","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(99)70497-4","article-title":"Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis","volume":"40","author":"Egan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0355","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-\u03b1 treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0360","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Ar\u00e9valo","year":"2000","journal-title":"J Trauma"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0365","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1046\/j.1365-4362.1998.00451.x","article-title":"Drugs causing fixed eruptions: A study of 450 cases","volume":"37","author":"Mahboob","year":"1998","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0370","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1525-1470.1995.tb00149.x","article-title":"Clinical pattern of cutaneous drug eruption among children and adolescents in north India","volume":"12","author":"Sharma","year":"1995","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0375","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-4632.2006.02853.x","article-title":"Fixed drug eruption (FDE): changing scenario of incriminating drugs","volume":"45","author":"Sehgal","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0380","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0022-3476(99)70472-5","article-title":"Fixed drug eruptions in children","volume":"134","author":"Morelli","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0385","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/archderm.1996.03890330150036","article-title":"Cross-reactivity in fixed drug eruptions to tetracyclines","volume":"132","author":"Tham","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0390","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-4362.1981.tb02011.x","article-title":"Fixed eruption due to two unrelated drugs: Oxyphenbutazone and tetracycline","volume":"20","author":"Bhargava","year":"1981","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0395","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0190-9622(03)01588-3","article-title":"Specific site involvement in fixed drug eruption","volume":"49","author":"\u00d6zkaya-Bayazit","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0400","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/ACI.0b013e32832d565c","article-title":"Role of T cells in nonimmediate allergic drug reactions","volume":"9","author":"Rozieres","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0405","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1365-2133.2008.08516.x","article-title":"In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption","volume":"158","author":"Mizukawa","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0410","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/ACI.0b013e32832cda4c","article-title":"Fixed drug eruption: pathogenesis and diagnostic tests","volume":"9","author":"Shiohara","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0415","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0091-6749(03)01624-5","article-title":"IFN-\u03b3\u2013producing effector CD8 + T cells and IL-10\u2013producing regulatory CD4 + T cells in fixed drug eruption","volume":"112","author":"Teraki","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0420","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1525-1470.1988.tb00907.x","article-title":"Fixed drug eruption at the site of BCG vaccination","volume":"5","author":"Kanwar","year":"1988","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0425","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/archderm.1972.01620140019006","article-title":"Fixed drug eruption (phenolphthalein): Evidence for a blood-borne mediator","volume":"106","author":"Wyatt","year":"1972","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0430","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1365-4362.1991.tb04354.x","article-title":"Drug-specific clinical pattern in fixed drug eruptions","volume":"30","author":"Thankappan","year":"1991","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0435","first-page":"138","article-title":"Fixed drug eruption: Skin focus","volume":"21","author":"Gantsho","year":"2008","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0440","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.addbeh.2013.03.020","article-title":"Purple drank prevalence and characteristics of misusers of codeine cough syrup mixtures","volume":"38","author":"Agnich","year":"2013","journal-title":"Addict Behav"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0445","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2133.1987.tb05879.x","article-title":"Topical provocation of fixed drug eruption","volume":"116","author":"Alanko","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0450","first-page":"120","article-title":"Drugs causing fixed drug eruptions: Confirmed by provocation tests","volume":"69","author":"Gupta","year":"2003","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0455","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-0536.1998.tb05739.x","article-title":"Topical provocation in 31 cases of fixes drug eruption: Change of causative drugs in 10 years","volume":"38","author":"Lee","year":"1998","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0460","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP)\u2014a clinical reaction pattern","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0465","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archderm.140.9.1172","article-title":"Acute generalized exanthematous pustulosis in children","volume":"140","author":"Ersoy","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0470","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0475","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1525-1470.2000.017005399.x","article-title":"Acute generalized exanthematous pustulosis (AGEP), an uncommon condition in children: Case report and review of the literature","volume":"17","author":"Meadows","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0480","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","article-title":"Acute generalized exanthematous pustulosis (AGEP): A review and update","volume":"73","author":"Szatkowski","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0485","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jaad.2014.03.007","article-title":"A rapidly progressive and fatal case of atypical acute generalized exanthematous pustulosis","volume":"71","author":"Krishna","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0490","first-page":"452","article-title":"Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis","volume":"151","author":"Navarini","year":"2015","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0495","first-page":"410","article-title":"Profile of acute generalized exanthematous pustulosis in Israel during 2002-2005: Results of the RegiSCAR Study","volume":"10","author":"Davidovici","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0500","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaad.2006.05.010","article-title":"Acute generalized exanthematous pustulosis following a spider bite: Report of 3 cases","volume":"55","author":"Davidovici","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0505","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/S0002-9440(10)64486-0","article-title":"Acute generalized exanthematous pustulosis: Role of cytotoxic T cells in pustule formation","volume":"161","author":"Schmid","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0510","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bjd.12502","article-title":"Systemic involvement of acute generalized exanthematous pustulosis: A retrospective study on 58 patients","volume":"169","author":"Hotz","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0515","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/ndt\/17.10.1857","article-title":"Acute reversible renal failure in acute generalized exanthematous pustulosis","volume":"17","author":"Brandenburg","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-014-0442-8","article-title":"Skin testing and patch testing in non-IgE-mediated drug allergy","volume":"14","author":"Barbaud","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.clindermatol.2017.08.007_bb0525","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/archderm.139.9.1181","article-title":"A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis","volume":"139","author":"Mashiah","year":"2003","journal-title":"Arch Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X17301281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X17301281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T07:18:12Z","timestamp":1602659892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X17301281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":105,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0738081X17301281"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2017.08.007","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous adverse drug reactions: Kids are not just little people","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2017.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}